161 related articles for article (PubMed ID: 37937606)
21. Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.
Gross AM; Plotkin SR; Watts NB; Fisher MJ; Klesse LJ; Lessing AJ; McManus ML; Larson AN; Oberlander B; Rios JJ; Sarnoff H; Simpson BN; Ullrich NJ; Stevenson DA
Clin Trials; 2024 Feb; 21(1):29-39. PubMed ID: 37772407
[TBL] [Abstract][Full Text] [Related]
22. Neurofibromatosis: part 2--clinical management.
Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
[TBL] [Abstract][Full Text] [Related]
23. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
[TBL] [Abstract][Full Text] [Related]
24. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
[TBL] [Abstract][Full Text] [Related]
25. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
Vranceanu AM; Merker VL; Park E; Plotkin SR
J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
[TBL] [Abstract][Full Text] [Related]
26. Neurofibromatosis-related tumors: emerging biology and therapies.
Karajannis MA; Ferner RE
Curr Opin Pediatr; 2015 Feb; 27(1):26-33. PubMed ID: 25490687
[TBL] [Abstract][Full Text] [Related]
27. Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes.
Perez-Becerril C; Evans DG; Smith MJ
Hum Mutat; 2021 Oct; 42(10):1187-1207. PubMed ID: 34273915
[TBL] [Abstract][Full Text] [Related]
28. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1.
Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Schneider KW; Scott HS; Plon SE; Tabori U
Clin Cancer Res; 2017 Jun; 23(12):e46-e53. PubMed ID: 28620004
[TBL] [Abstract][Full Text] [Related]
29. Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.
Thompson HL; Grabowski J; Franklin B; Koetsier KS; Welling DB
Clin Trials; 2024 Feb; 21(1):18-28. PubMed ID: 38321701
[TBL] [Abstract][Full Text] [Related]
30. Advances in the treatment of neurofibromatosis-associated tumours.
Lin AL; Gutmann DH
Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
[TBL] [Abstract][Full Text] [Related]
31. A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses.
Acar S; Nieblas-Bedolla E; Armstrong AE; Hirbe AC
Pediatr Neurol; 2022 Sep; 134():1-6. PubMed ID: 35759947
[TBL] [Abstract][Full Text] [Related]
32. Neurofibromatosis type 2 (NF 2) or schwannomatosis?--Case report study and diagnostic criteria.
Radek M; Tomasik B; Wojdyn M; Snopkowska-Wiaderna D; Błaszczyk M; Radek A
Neurol Neurochir Pol; 2016; 50(3):219-25. PubMed ID: 27154453
[TBL] [Abstract][Full Text] [Related]
33. Neurofibromatosis.
McClatchey AI
Annu Rev Pathol; 2007; 2():191-216. PubMed ID: 18039098
[TBL] [Abstract][Full Text] [Related]
34. Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis.
Burns R; Niendorf K; Steinberg K; Mueller A; Ly I; Jordan JT; Plotkin SR; Hicks SR
Am J Med Genet A; 2022 Aug; 188(8):2413-2420. PubMed ID: 35638454
[TBL] [Abstract][Full Text] [Related]
35. Pediatric schwannomatosis, a rare but distinct form of neurofibromatosis.
Thomas AK; Egelhoff JC; Curran JG; Thomas B
Pediatr Radiol; 2016 Mar; 46(3):430-5. PubMed ID: 26546566
[TBL] [Abstract][Full Text] [Related]
36. Distinctive low epidermal nerve fiber density in schwannomatosis patients provides a major parameter for diagnosis and differential diagnosis.
Farschtschi SC; Kluwe L; Schön G; Friedrich RE; Matschke J; Glatzel M; Weis J; Hagel C; Mautner VF
Brain Pathol; 2020 Mar; 30(2):386-391. PubMed ID: 31424590
[TBL] [Abstract][Full Text] [Related]
37. Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2-related schwannomatosis.
Halliday D; Emmanouil B; Evans DGR
Clin Genet; 2023 May; 103(5):540-552. PubMed ID: 36762955
[TBL] [Abstract][Full Text] [Related]
38. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders.
Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Druker H; Scott HS; Tabori U
Clin Cancer Res; 2017 Jun; 23(12):e54-e61. PubMed ID: 28620005
[TBL] [Abstract][Full Text] [Related]
39. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
Plotkin SR; Bredella MA; Cai W; Kassarjian A; Harris GJ; Esparza S; Merker VL; Munn LL; Muzikansky A; Askenazi M; Nguyen R; Wenzel R; Mautner VF
PLoS One; 2012; 7(4):e35711. PubMed ID: 22558206
[TBL] [Abstract][Full Text] [Related]
40. [Segmental schwannomatosis in upper-extremity: 5 cases report and literature review].
Wang ZX; Chen SL; Yi CJ; Li C; Rong YB; Tian GL
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Oct; 45(5):698-703. PubMed ID: 24136261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
